OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The aim is to create new genomics solutions that could combat cancer and advance market access
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The profits were bolstered by the Boehringer Ingelheim MEK program income
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Subscribe To Our Newsletter & Stay Updated
